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Abstract
The worldwide prevalence of obesity more than doubled between 1980 and 2014. The obesity pandemic is tightly
linked to an increase in energy availability, sedentariness and greater control of ambient temperature that have
paralleled the socioeconomic development of the past decades. The most frequent cause which leads to the
obesity development is a dysbalance between energy intake and energy expenditure. The gut microbiota as an
environmental factor which influence whole-body metabolism by affecting energy balance but also inflammation
and gut barrier function, integrate peripheral and central food intake regulatory signals and thereby increase body
weight. Probiotics have physiologic functions that contribute to the health of gut microbiota, can affect food intake
and appetite, body weight and composition and metabolic functions through gastrointestinal pathways and
modulation of the gut bacterial community.
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Background
Overweight and obesity are defined as abnormal or ex-
cessive fat accumulation that may impair health. Body
mass index (BMI), defined as the weight in kilograms di-
vided by the height in meters squared (kg/m2), is index
that commonly used to classify overweight and obesity
in adults due to its low cost and simplicity. The World
Health Organization (WHO) [1] has defined overweight
as having a BMI between 25.0 and 29.9 kg/m2; and obes-
ity as having a BMI greater or equal than 30.0 kg/m2.
The worldwide prevalence of obesity more than dou-
bled between 1980 and 2014 and for today WHO has
declared obesity as global epidemic and took it under
control. In 2014, more than 1.9 billion adults older than
18 years (39 %) are overweight. Overall, about 13 % or
600 million of these adult population (11 % of men and
15 % of women) were obese [1].
According to WHO the Global Database on BMI the
prevalence of obesity is different globally and have sex-
specific features. As of November 2004, the database
include data from 350 separate surveys conducted over a
1942–2002 and has compiled results from a total of 97
countries and territories covering approximately 86 % of
the adult population worldwide [2]. The highest preva-
lence of obesity is observed in the Pacific Islands and
reach up to 80 % in some regions. The obesity rate less
than 1 % has been reported in India [3].
In Europe, as for 2014, in general the incidence of obes-
ity is high but geographically wide variations has been re-
ported. The lowest rate observed in Tajikistan (13.5 %)
and highest in Andorra and Turkey (29.4 %) [1].
More than 80 % of countries reported nationally
gender-specific data related to prevalence of obesity or
overweight in population. In majority of countries lo-
cated in Africa, Latin America, Asia and Oceania the
higher levels of overweight amongst women has been re-
ported. In contrast to these regions in Europe and North
America male’s overweight prevalence rates were more
pronounced [2].
The National Health and Nutrition Examination
Survey (NHANES) is another cross-sectional, nationally
representative series of survey of 4115 adult men and
women conducted in 1999 and 2000 by the National
Center for Health Statistics of the U.S. Centers for
Disease Control and Prevention. The age-adjusted
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prevalence of obesity and overweight in U.S. adults were
30.5 and 64.5 % respectively in 1999–2000 compared with
22.9 and 55.9 % in NHANES III (1988–1994; P < .001).
Racial/ethnic groups did not differ significantly in the
prevalence of obesity or overweight [4]. More recent data
from NHANES show no significant changes in the preva-
lence of obesity for either men or women between 2003–
2004 and 2005–2006 [5]. Interestingly that obesity preva-
lence was relatively low and stable between 1960 and
1980, but more than doubled from 15 % in 1980 to 34 %
in 2006 [6] and keep the same rate and in nowadays –
33.4 % due to WHO-2014 data [1]. This possible
stabilization in the obesity trends may be an early sign of a
plateau in the obesity epidemic.
Children obesity is very important problem in whole
word. In 2013, 42 million children under the age of 5
were overweight or obese. USA takes first place in the
world for prevalence of obesity [1]. Childhood obesity
has more than doubled in children and quadrupled in
adolescents in the past 30 years [7]. The percentage of
children aged 6–11 years in the U.S. who were obese in-
creased from 7 % in 1980 to nearly 18 % in 2012. Simi-
larly, the percentage of adolescents aged 12–19 years
who were obese increased from 5 % to nearly 21 % over
the same period [8]. In this country main factors con-
tributing to the weight gain are widespread net of fast
food restaurants and hypodynamic.
According to a new report published by the WHO
Regional Office for Europe, the country profiles being
overweight is so common that it risks becoming a new
norm in the WHO European Region [9]. For example,
up to 27 % of 13-year-olds and 33 % of 11-year olds are
overweight. Among 11-year-old boys and girls, the
prevalence of overweight was highest in Greece (33 %),
Portugal (32 %), Ireland (30 %) and Spain (30 %) and
lowest in the Netherlands (13 %) and Switzerland
(11 %) [9].
The most frequent cause which leads to the obesity
development is a dysbalance between energy intake and
energy expenditure. In this complex process genetic sus-
ceptibility, environmental and lifestyle factors are involved.
Current research efforts have focused on host and envir-
onmental factors that may affect energy balance.
Recent advances in next generation sequencing tech-
nology and mechanistic testing in gnotobiotic mice have
identified the gut microbiota as an environmental factor
which influence whole-body metabolism by affecting
energy balance but also inflammation and gut barrier
function, integrate peripheral and central food intake
regulatory signals and thereby increase body weight.
Underlying mechanisms whereby the gut microbiota
contributes to host metabolism were revealed from stud-
ies on germ-free mice which were protected against
developing diet-induced obesity [10, 11].
Consequently, the gut microbiota is gaining significant
research interest in relation to obesity in an attempt to
better understand the etiology of obesity and potentially
new methods of its prevention and treatment [12].
Pathophysiology of obesity and role of intestinal
microflora in the metabolic steady state
The pathophysiology of obesity is multifactorial, and not
completely understood. The obesity pandemic is tightly
linked to an increase in energy availability, sedentariness
and greater control of ambient temperature that have
paralleled the socioeconomic development of the past
decades [13]. Genetic factors also play a key role in de-
termining body weight, with heritability estimates for
the variance in body mass index ranging between 40 and
70 % [14, 15]. Epigenetic factors may also be involved
[16]. For the purpose of this review, we will focus on the
role of intestinal microflora in the pathophysiology of
obesity and obesity-related metabolic alterations.
In recent years, intestinal microflora has received in-
creasing attention as a metabolic gateway between the
outer environment and the host, particularly with regard
to modulation of inflammation, energy metabolism and
body weight homeostasis. Human intestinal microflora
represents a complex ecosystem consisting of trillions of
microorganisms and thousands of bacterial species that
are deeply involved in different functions of host
metabolism [17]. A causal link between intestinal micro-
flora and host metabolism was first provided when
Turnbaugh et al. demonstrated that transplanting the in-
testinal microflora from obese mice could replicate the
obese phenotype in germ-free mice [11]. Differences in
intestinal microflora composition between humans seem
to represent a key factor affecting energy homeostasis
[18]. In both mice and humans, two bacterial phyla are
dominant in the gut, the Gram-negative Bacteroidetes
and the Gram-positive Firmicutes [18, 19]. Although few
data exist at the genus and species level, studies in mice
and in humans have demonstrated that obesity is associ-
ated with a reduction in the relative abundance of
Bacteroidetes [18, 20, 21], and that the obese microflora
has lower bacterial diversity than lean microflora [20, 22].
In overweight/obese humans, low faecal bacterial gene
richness is associated with more marked overall adiposity
and dyslipidaemia, impaired glucose homeostasis and
higher low-grade inflammation [23, 24].
Intestinal microflora composition is strongly affected
by dietary patterns. A high-fat and high-sugar Western
diet increases the relative abundance of Firmicutes at
the expense of the Bacteroidetes in animal models [22],
whereas low-calorie diet induced weight loss may in-
crease the relative abundance of Bacteroidetes in obese
individuals [25]. Data obtained in animal models of the
human intestinal ecosystem indicate that switching from
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a low-fat, plant polysaccharide-rich diet to a high-fat/
high-sugar “Western” diet may shift the structure of the
microflora within a single day, changing the representa-
tion of metabolic pathways and altering microbiome
gene expression [26]. Consistently, a controlled-feeding
study in humans showed that microflora composition
changed detectably within 24 h of initiating a high-fat/
low-fibre or low-fat/high-fibre diet, although the magni-
tude of the changes was modest [27]. Kong et al. ex-
plored differences in host inflammatory variables and
intestinal microflora in function of three distinct dietary
clusters in overweight/obese subjects. They found that
subjects having a healthier dietary pattern (higher con-
sumption of fruits, yogurt and soups and lower con-
sumption of sweets, confectionary and table sugar and
sugary drinks) showed less pronounced metabolic im-
pairment and had the highest gene richness and diversity
in their intestinal microflora, despite there was no differ-
ence in total energy intake or body weight across dietary
clusters [28].
Several mechanisms by which the intestinal microflora
may affect body weight have been proposed. The intes-
tinal microflora of obese subjects may be more efficient
at extracting energy from a given diet than the intestinal
microflora of lean individuals [10, 11], which may lead
to increased energy storage and adiposity. Another
mechanism by which intestinal microflora may modulate
energy intake and metabolism is the production of short
chain fatty acids (SCFAs) from indigestible polysaccha-
rides. SCFAs such as acetate, butyrate and propionate
produced by bacterial fermentation function as energy
substrates, as well as regulators of satiety and food in-
take [29]. By activating the G-protein-coupled receptors
GPR41 and GPR43 on intestinal epithelial cells, SCFAs
stimulate peptide YY (PYY) and glucagon-like peptide
(GLP)-1 secretion. In turn, these hormones may sup-
press gut motility and retard intestinal transit, allowing
for greater nutrient absorption [30, 31]. On the other
hand, butyrate and propionate have been reported to re-
duce food intake and to protect against diet-induced
obesity and insulin resistance in mice [32], greater bac-
terial gene richness has been associated with a higher
production of SCFAs [24], and propionate-producer bac-
teria such as Akkermansia muciniphila may improve the
metabolic profile in mice [33]. However, the role of
SCFAs in the regulation of host metabolism has yet to
be fully clarified. Finally, it has even been suggested that
in Western societies the increased use of antibiotic treat-
ment, i.e. one important factor that can affect microflora
composition, may be associated with weight gain or
obesity in humans [34].
A large body of evidence indicates that associations
exist between alterations in intestinal microflora func-
tion and/or composition and metabolic derangements
tightly linked to obesity, such as insulin resistance,
atherosclerosis and low-grade chronic inflammation.
Chronic low-grade inflammation appears to be a major
factor in the development of obesity-related metabolic
disturbances [35–37]. Studies in mice indicate that high-
fat diet may result in changes in intestinal microflora
composition and increased levels of circulating endo-
toxins such as lipopolysaccharide (LPS), and that infu-
sion of LPS causes low-grade chronic inflammation and
most of the features of the early onset of metabolic dis-
eases, such as visceral fat deposition, glucose intolerance
and hepatic insulin resistance [38]. LPS has been there-
fore postulated to be the molecular link between intes-
tinal microflora and the chronic low-grade inflammation
induced by a high-fat diet that leads to insulin resistance
[39–41]. Abnormally increased gut permeability to bac-
teria and their products is a factor that further contrib-
utes to insulin resistance and oxidative stress [42, 43].
Consistently, observations in mice indicate that intes-
tinal microflora influences energy metabolism and has
systemic effects on host lipid metabolism, especially tri-
glycerides and phosphatidylcholine [44]. The intestinal
microflora has been shown to metabolize the dietary
lipid phosphatidylcholine to trimethyl amine, which pro-
motes atherosclerosis and inflammation in mice [45]. Of
note, sequencing of the gut metagenome of patients with
symptomatic atherosclerotic plaques revealed that
symptomatic atherosclerosis is associated with an altered
gut metagenome [46]. Finally, even tissue fatty acid com-
position may be modulated by intestinal microflora:
beneficial intestinal Lactobacilli and Bifidobacteria can
synthesize bioactive isomers of conjugated linoleic acid
that have antidiabetic, anti-atherosclerotic, immuno-
modulatory, and anti-obesity properties [47].
Of note, the presence of obesity-related metabolic dis-
turbances varies widely among obese individuals [48]. It
would be interesting to explore whether differences in
intestinal microflora have a role in determining the
metabolically healthy and unhealthy obese phenotypes.
Review of experimental studies
Preclinical evidence supporting the “anti-obesity” effects
of probiotics mainly comes from studies on probiotics
belonging to the genus Lactobacillus. Some other studies
have focused on the use of Bifidobacterium strains.
Convincing evidence from animal studies suggests that
probiotic administration may reduce, at least in part, the
amount of weight gained in response to a high-fat diet
(HFD). Probiotic supplementation with Lactobacillus
curvatus HY7601 or Lactobacillus curvatus HY7601 in
combination with Lactobacillus plantarum KY1032 ef-
fectively suppressed body weight gain and reduced the
adipose tissue weight in mice fed a high-fat high-
cholesterol diet for 9 weeks [49]. In another study by the
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same group, mice were fed a HFD for 8 weeks to induce
obesity, and then randomized to receive HFD plus
Lactobacillus curvatus HY7601 and Lactobacillus plan-
tarum KY1032 or placebo for another 10 weeks. Mice
fed normal chow served as controls. Following probiotic
treatment, body weight gain was 38 % lower in the pro-
biotic group than in the placebo group, although mice
supplemented with probiotics still gained more weight
than controls. Interestingly, the food efficiency ratio was
reduced by a significant 29 % in mice supplemented with
probiotics, indicating lower weight gain per grams of
food consumed [50]. In keeping with these observations,
it has recently been reported that 12-week dietary sup-
plementation with either Lactobacillus paracasei CNCM
I-4270, Lactobacillus rhamnosus I-3690 or Bifidobacter-
ium animalis subsp. lactis I-2494 significantly attenuated
HFD-induced weight gain despite no reductions in food
intake in mice [51]. Similar results have been obtained
in studies where Bifidobacterium spp. (B. pseudocatenu-
latum SPM 1204, B. longum SPM 1205, and B. longum
SPM 1207 [52] or B. adolescentis [53]) was added to a
HFD in rats.
Other probiotics shown to have anti-obesity effects in-
clude the plant-derived lactic acid bacterium Pediococcus
pentosaceus LP28 [54], Bacteroides uniformis CECT
7771 [55] and Akkermansia muciniphila [33]. The latter
is a mucin-degrading bacterium that resides and abun-
dantly colonizes the mucus layer. The amount of these
bacteria negatively correlates with body weight and de-
creases in response to a HFD [56]. Moreover, daily ad-
ministration of A. muciniphila to HFD-induced obese
mice for 4 weeks reduced body weight and improved
body composition (i.e., fat mass/lean mass ratio), with
no changes in food intake [33]. Finally the antiobesity
properties of a probiotic yeast were examined for the
first time in a recent study by Everard and coll [56].
Saccharomyces boulardii Biocodex administration re-
duced body weight gain and fat mass in obese and type
2 diabetic mice, and significantly changed the gut micro-
biota composition with an increased proportion of
Bacteroidetes and a decreased amount of the phyla
Firmicutes, Proteobacteria, and Tenericutes [56].
Importantly, preclinical evidence seems to indicate
that the benefits on body weight translate into
favourable metabolic effects, i.e. improvements in insulin
resistance/glycemic control, amelioration of lipid profile
and prevention of non-alcoholic fatty liver disease
(NAFLD). Among others, the probiotic bacterial strain
Lactobacillus rhamnosus GG (LGG) has been consist-
ently shown to exert beneficial effects on glucose
homeostasis. Treatment with LGG for 13 weeks during
HFD in mice improved insulin sensitivity and reduced
lipid accumulation by stimulating adiponectin secretion
and consequent activation of AMPK, a key enzyme that
controls cellular energy status [57]. Tabuchi and coll.
showed that LGG decreased glycated hemoglobin and
ameliorated glucose tolerance in streptozotocin-induced
diabetic rats, possibly due to prevention of a decrease in
insulin secretion [58]. More recently, it has been pro-
posed that the anti-diabetic effect of LGG may be due to
a reduction in endoplasmic reticulum stress and sup-
pressed macrophage activation, which result in enhanced
insulin sensitivity [59]. Several other probiotic strains
have been tested as agents with potential antidiabetic ef-
fects. Administration of Lactobacillus curvatus HY7601
and Lactobacillus plantarum KY1032 prevented the
development of high-fructose diet-induced metabolic
syndrome, i.e. lowered plasma glucose, insulin and tri-
glycerides levels. These effects were associated with a
reduction in oxidative stress [50]. Studies using the
traditional Indian yoghurt – dahi supplemented with
probiotic strains of Lactobacillus acidophilus and Lacto-
bacillus casei have shown that this product can improve
the stigmata of diabetes, i.e. hyperglycemia and hyperin-
sulinemia, in high-fructose induced rat models of
diabetes [60, 61]. Dietary supplementation with Lactoba-
cillus paracasei CNCM I-4270, Lactobacillus rhamnosus
I-3690 or Bifidobacterium animalis subsp. lactis I-2494
was shown to significantly attenuate HFD-induced
hyperinsulinemia, hyperglycemia and glucose intolerance
in mice [51]. Bifidobacterium adolescentis prevented in-
sulin resistance in rats fed a HFD; interestingly, supple-
mentation with this probiotic blunted the reduction in
pancreas weight induced by the HFD, which may be re-
lated to the observed preservation of insulin sensitivity
[53]. Finally, treatment with A. muciniphila for 4 weeks
completely reversed diet-induced fasting hyperglycemia,
possibly via a reduction in gluconeogenesis, and reduced
insulin resistance in HFD-induced obese mice [33].
Probiotic supplementation also appears to be associ-
ated with a favorable effect on NAFLD, although differ-
ent Lactobacillus and Bifidobacterium strains have
specific effects on markers of obesity in rodent models.
The analysis of more than 20 articles from 2013 to July
2014 by Cani and coll. showed that at least 15 different
strains of Lactobacillus and three strains of Bifidobacter-
ium do not equally influence on hepatic lipids and
NAFLD development on different animal models.
Remarkably, 12 strains decreased hepatic tissue inflam-
mation and 11 reduced the hepatic triglyceride content
when given as a single treatment [62].
Short-term courses of probiotic mixtures containing
concentrated biomass of 14 alive probiotic strains
(Lactobacillus, Lactococcus, Bifidobacterium, Propioni-
bacterium, Acetobacter) from childhood was shown to
reduce significantly total body and visceral adipose tissue
weight, together with improvement in insulin sensitivity
[63] and prevention of NAFLD development [64] in
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mice neonatally treated with monosodium glutamate.
Similarly, administration of LGG protected mice from
NAFLD development induced by a high-fructose diet
through an increase of beneficial bacteria, restoration of
gut barrier function and subsequent attenuation of liver
inflammation and steatosis [65]. A recent study com-
pared the effects of four Bifidobacteria strains (Bifido-
bacteria L66-5, L75-4, M13-4 and FS31-12) on lipid
metabolism in high-fat diet obese mice. All four strains
were associated with reductions in serum and liver tri-
glycerides, and significantly alleviated lipid deposition in
liver. Only Bifidobacterium L66-5 and Bifidobacterium
FS31-12 decreased cholesterol liver content significantly
[66]. Oral supplementation of Bifidobacterium adoles-
centis for 12 weeks was shown to protect C57BL/6 mice
against diet-induced non-alcoholic steatohepatitis
(NASH). Furthermore, mice treated with the probiotic
had significantly decreased liver damage, which associ-
ated with prevention from lipid peroxidation, NFκB
activation and finally inflammation in the liver [67].
Plaza-Diaz and coll. evaluated the effects of Lactoba-
cillus paracasei CNCM I-4034, Bifidobacterium breve
CNCM I-4035 and Lactobacillus rhamnosus CNCM I-
4036 probiotic strains and their mixture on the devel-
opment of hepatic steatosis as compared to placebo
in Zucker rats with genetically determined obesity. In
this study, only single-strain probiotic of Lactobacillus
rhamnosus or Bifidobacterium breve and the mixture
of Bifidobacterium breve and Lactobacillus paracasei
decreased triacylglycerol content in liver and counter-
acted the development of hepatic steatosis in part by
lowering serum LPS [68]. However, in another study,
Lactobacillus paracasei CNCM I-4270, Lactobacillus
rhamnosus I-3690 or Bifidobacterium animalis subsp.
lactis I-2494 administered individually were all shown
to protect against HFD-induced hepatic steatosis [51].
Finally, probiotics containing Lactobacillus curvatus
HY7601 significantly reduced liver fat accumulation
as compared to Lactobacillus plantarum KY1032 in
diet-induced obesity. Combination of this probiotic
was more effective for inhibiting gene expressions of
various fatty acid synthesis enzymes in the liver, con-
comitant with decreases in fatty acid oxidation-related
enzyme activities and their gene expressions [49].
Data from animal studies summarized in Table 1.
In summary, several preclinical studies have been con-
ducted that used different bacterial strains, animal
models and length of administration. Nearly all studies
have shown some anti-obesity property of probiotics.
Modulation of energy homeostasis (e.g. reduction in the
food efficiency ratio) and anti-inflammatory/anti-oxidant
effects appear to underlie the beneficial properties of
probiotics. However, despite a large body of evidence
supporting the anti-obesity and favourable metabolic
effects of probiotics, it should be borne in mind that
these effects may vary dramatically, depending both on
the bacterial strain and on the host [69].
Critical review of clinical studies
Prevention and management of obesity is proposed to
begin in childhood when environmental factors exert a
long-term effect on the risk for obesity in adulthood.
Thus, identifying modifiable factors may help to reduce
this risk. Therefore, the search of new non-toxic means
of the obesity prevention is the urgent challenge of mod-
ern science. Recent evidence suggests that gut micro-
biota is involved in the control of body weight, energy
homeostasis and inflammation and thus, plays a role in
the pathophysiology of obesity. Prebiotics and probiotics
are of interest because they have been shown to alter the
composition of gut microbiota and to affect food intake
and appetite, body weight and composition and meta-
bolic functions through gastrointestinal pathways and
modulation of the gut bacterial community [70, 71].
In recent multicenter, double-blind, randomized,
placebo-controlled trial administration of fermented
milk containing Lactobacillus gasseri SBT2055 for
12 weeks lead to significant reduction of abdominal vis-
ceral and subcutaneous fat areas an average of 4.6 and
3.3 % respectively as measured by computed tomog-
raphy. Body weight and BMI also decreased significantly
approximately on 1.5 % (P < 0.001) only in active treated
group suggesting beneficial influence of Lactobacillus
gasseri on metabolic disorders [72].
This study evaluate the impact of perinatal probiotic
intervention on childhood growth patterns and the de-
velopment of overweight during a 10-year follow-up.
Administration of Lactobacillus rhamnosus GG started
4 weeks before expected delivery with extension for
6 months postnatally modify the growth pattern of the
child by restraining excessive weight gain during the first
years of life. The most pronounced changes were ob-
served at the age of 4 years (P = 0.063), with lack of effi-
ciency in the later stages of development [73].
In this systematic review, which include 5 human trial
reports, were analyzed the role of probiotics, basically
containing Lactobacillus sub-strains, in metabolic pa-
rameters modulation in patients with type 2 diabetes.
The significant reduction of at list one of the primary
outcome endpoints which include levels of fasting
plasma glucose, postprandial blood glucose, HbA1c, in-
sulin, insulin resistance and onset of diabetes were dem-
onstrated in all studies. Regarding secondary outcome
measures, i.e. lipid profiles, pro-inflammatory and anti-
oxidant factors, only one human study failed to show
any significant changes in any of these parameters [74].
Furthermore, in obese patients with metabolic syndrome,
improvement of insulin sensitivity (median rate of glucose
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Table 1 Summary from animal studies of impact probiotic strains on obesity and associated diseases
Study Experimental model of obesity Type of probiotics Duration of intervention Key findings
Yoo et al. 2013 [49] high-fat high-cholesterol
diet (HFHCD)
Lactobacillus curvatus HY7601
alone or in combination with
Lactobacillus plantarum KY1032
9 weeks parallel with HFHCD ↓ body weight gain
↓ hepatic lipid droplet accumulation and adipocyte size
↓ cholesterol in plasma and liver
↓ gene expressions fo fatty acid synthesis enzymes
↓ proinflammatory cytokines (TNF-α, IL-1b)
Park et al. 2013 [50] HFD/placebo or normal




10 weeks after HFD ↓ body weight gain and fat accumulation
↓plasma insulin, leptin, total-cholesterol and liver toxicity
biomarkers
↓ pro-inflammatory genes (TNFα, IL6, IL1β and MCP1) in
adipose tissue
↓ fatty acid oxidation-related genes (PGC1α, CPT1, CPT2
and ACOX1)in the liver
Wang et al. 2015 [51] HFD/placebo or normal chow Lactobacillus paracasei CNCM
I-4270, Lactobacillus rhamnosus
I-3690 or Bifidobacterium
animalis subsp. lactis I-2494
12 weeks parallel with HFD ↓ body weight gain
↓ macrophage infiltration into epididymal adipose tissue
↓ hepatic steatosis
↑ glucose–insulin homeostasis
Strain-specific attenuation of obesity comorbidities throth
impacts on MS-associated
phylotypes of gut microbiota in mice
An et al. 2011 [52] HFD/normal chow Lactic acid bacterium (LAB)
supplement (B. pseudocatenulatum
SPM 1204, B. longum SPM 1205,
and B. longum SPM 1207;
108 ~ 109 CFU)
7 weeks parallel with HFD ↓ body weight gain and fat accumulation
↓blood serum levels of total cholesterol, HDL-C, LDL-C,
triglyceride, glucose, leptin
↓liver toxicity biomarkers (AST, ALT)
Chen et al. 2012 [53] HFD/normal chow Bifidobacterium adolescentis 12 weeks parallel with HFD ↓ body weight gain and visceral fat accumulation
↑insulin sensitivity
Zhao et al. 2012 [54] HFD for 6 weeks/normal chow Pediococcus pentosaceus LP28 /
Lactobacillus plantarum SN13T
as comparator
8 weeks after HFD ↓ body weight gain, visceral fat accumulation and liver
lipid contents (triglyceride and cholesterol)
↓ hepatic lipid droplet accumulation and adipocyte size
↓ lipid metabolism-related genes (CD36, SCD1, PPARγ)
Gauffin et al. 2012 [55] HFD/normal chow Bacteroides uniformis CECT 7771 7 weeks parallel with HFD ↓body weight gain, visceral fat accumulation and liver
lipid contents (triglyceride and cholesterol)
↑small adipocyte numbers
↓serum cholesterol, triglyceride, glucose, insulin and
leptin levels,
↑oral tolerance to glucose
↓dietary fat absorption (reduced number of fat micelles
in enterocytes)
↑ immune defence mechanisms
Everard et al. 2013 [33] HFD/normal chow Akkermansia muciniphila
(alive versus heat- killed)
4 weeks parallel with HFD ↓body weight gain
↓metabolic endotoxemia and adipose tissue inflammation
↓insulin resistance
↑intestinal levels of endocannabinoids that control
inflammation, the gut barrier, and gut peptide secretion
- all these effects required alive A. muciniphila because
treatment with heat-killed cells did not improve the














Table 1 Summary from animal studies of impact probiotic strains on obesity and associated diseases (Continued)
- administration of prebiotics (oligofructose) to ob/ob mice
increased the abundance of A. muciniphila by ∼ 100-fold.
Everard et al. 2014 [56] db/db mice/placebo (vehicle) Saccharomyces boulardii Biocodex 4 weeks ↓body weight gain and fat mass
↓hepatic steatosis and total liver lipids content
↓decreases hepatic (50 % decrease in CD11c macrophages
level, F4/80, IL-1β and MCP-1mRNA)
↓systemic inflammation (↓plasma cytokine concentrations
of IL-6, IL-4, IL-1β and TNF-α).
Kim et al. 2013 [57] HFD/normal chow Lactobacillus rhamnosus GG 13 weeks parallel with HFD ↓body weight gain and fat mass
↑insulin sensitivity,
↑expression of genes related to glucose metabolism
(GLUT4 mRNA in skeletal muscle)
↑ adiponectin production in adipose tissue
↑ AMPK in skeletal muscle and adipose tissue
Tabuchi et al. 2003 [58] Neonatally streptozotocin-induced
diabetic rats/placebo (vehicle)
Lactobacillus rhamnosus GG 10 weeks ↓ HbA1c
↑oral tolerance to glucose
Park et al. 2015 [59] db/db mice/placebo (vehicle) Lactobacillus rhamnosus GG 4 weeks ↑ glucose tolerance
↑insulin-stimulated Akt phosphorylation and GLUT4
translocation in skeletal muscle
↓endoplasmic reticulum (ER) stress in skeletal muscle
↓M1-like macrophage activation in white adipose tissues
↑insulin sensitivity
Yadav et al. 2006 [60] high-fructose diet/normal chow Lactococcus lactis 42 days parallel with
high-fructose diet
↓ HbA1c
↓fasting blood glucose, insulin, free fatty acids and triglyceride
Yadav et al. 2007 [61] high-fructose diet/normal chow Lactobacillus casei/Lactobacillus
acidophilus
8 weeks parallel with
high-fructose diet
↓ HbA1c
↓fasting blood glucose plasma insulin, total cholesterol,
triacylglycerol, LDL-cholesterol, VLDL-cholesterol and blood
free fatty acids
↓liver glycogen
↓thiobarbituric acid-reactive substances and
↑ reduced glutathione in liver and pancreatic tissues
Ritze et al. 2014 [65] high-fructose diet/without control Lactobacillus rhamnosus GG 8 weeks parallel with
high-fructose diet
↓ liver inflammation and steatosis (protection from
NAFLD development)
↓duodenal IκB protein levels and restoration of the
duodenal tight junction protein concentration
↓ portal LPS
↓ TNF-α, IL-8R and IL-1β mRNA expression in the liver
Yin et al. 2010 [66] HFD/normal chow Bifidobacteria L66-5, L75-4, M13-4
and FS31-12
6 weeks parallel with HFD ↓liver triglyceride, total cholesterol and total lipid deposition
(all 4 strains, but in strain-dependent manner, more
pronounced for B. L66-5)
↓serum triglyceride and total cholesterol (all 4 strains,
but in strain-dependent manner, more pronounced for
B. L66-5 and B. FS31-12)
↓ body weight gain - B. L66-5
↑ body weight gain - B. M13-4No changes in body













Table 1 Summary from animal studies of impact probiotic strains on obesity and associated diseases (Continued)
Reichold A et al. 2014 [67] HFD/normal chow Bifidobacteria adolescentis 12 weeks parallel with HFD ↓ body weight gain
↓liver inflammation and steatosis (protection from
NASH development)
↓ formation of reactive oxygen species
↓ activation of NFκB
No effect on portal LPS, TLR-4 and Myd-88 mRNA expression
in livers
Plaza-Diaz et al. 2014 [68] ob/ob mice/placebo (vehicle) Lactobacillus paracasei CNCM
I-4034, Bifidobacterium breve
CNCM I-4035 and Lactobacillus
rhamnosus CNCM or mixture
of 3 strains
30 days ↓ triacylglycerol liver content (for L. rhamnosus, B. breve
or the mixture)
↓ neutral lipids liver content (for all four probiotic groups)
↓ serum LPS levels (for all four probiotic groups)
↓ serum TNF-α levels (for B. breve, L. rhamnosus or the mixture)
↓ serum IL-6 levels (for L. paracasei)
Savcheniuk O et al. 2014 [63, 64] Monosodium glutamate (MSG)
induced obesity/placebo (vehicle)




3 month ↓body weight gain and visceral fat accumulation
↓liver lipid contents (protection from NAFLD development)
↓serum cholesterol, triglyceride, glucose, insulin and leptin levels,













disappearance changed from 26.2 to 45.3 μmol/kg/min;
P < .05) were demonstrated after small intestinal micro-
biota translocation from lean donors [75]. In opposite to
this findings, Mazloom et al. also demonstrated that
6 weeks of oral treatment with probiotics contained
L. acidophilus, L. bulgaricus, L. bifidum and L. casei
decreased the concentration of triglycerides, IL-6 level
and insulin resistance in type 2 diabetic patients;
however the change were not significant [76].
Several clinical trials revealed promising effects of pro-
biotics in improving liver function, fat metabolism and
insulin resistance in patients with obesity related non-
alcoholic fatty liver disease (NAFLD). First clinical evi-
dence of beneficial effects of probiotics in patients with
chronic liver disease comes from the study reported by
Loguercio et al. in 2005 [77]. This trial comprised pa-
tients with NAFLD (n = 22), alcoholic fatty liver (n = 20),
chronic hepatitis C (n = 20), and cirrhosis (n = 16). In pa-
tients with NAFLD administration of probiotic VLS#3
for 3 months showed improvement in ALT levels, as
well as markers of lipid peroxidation, whereas significant
changes in serum cytokines (TNF-alpha, IL-6, and IL-10)
levels wasn’t observed as compared to patients with alco-
holic fatty liver [77].
In present randomized, placebo-controlled trial con-
ducted on 30 patients with histologically proven NAFLD
a probiotic mixture containing 500 million of Lactobacil-
lus bulgaricus and Streptococcus thermophilus per day
during 3 months lead to significant decreased of liver
aminotransferases activity only in active treated group.
Anthropometric parameters and cardiovascular risk
factors remained unchanged after treatment in both
groups [78].
In this report Malaguarnera et al., studied if inter-
vention of Bifidobacterium longum in combination
with prebiotics containing fructo-oligosaccharides for
24 weeks are superior to lifestyle modification alone
in the treatment of non-alcoholic steatohepatitis
(NASH). Undoubted advantage of this study that liver
biopsies were performed at entry and repeated for
histological changes assessment in post-treatment
period. In active treated group as compared to life-
style modification alone significant reduction of TNF-α,
CRP, serum AST levels, HOMA-IR and serum endotoxin.
Furthermore, administration of Bifidobacterium longum
in combination with prebiotics also lead to significant im-
provement of liver histology pattern. The mean NASH ac-
tivity index decreased from 9.44 (range 6–10) at baseline
to 3.22 (range 1–7) at 24 weeks [79].
In recent randomized clinical trial the treatment of
patient with NASH for 6-month with the Lepicol
probiotic formula contained Lactobacillus plantarum,
Lactobacillus deslbrueckii, Lactobacillus acidophilus,
Lactobacillus rhamnosus and Bifidobacterium bifidum
lead to significant changes in intrahepatic triglyceride con-
tent, as measured by proton-magnetic resonance spectros-
copy (22.6 ± 8.2 % to 14.9 ± 7.0 %; P = 0.034) as compared
to usual care group (16.9 ± 6.1 % to 16.0 ± 6.6 %; P = 0.55).
On the other hand, the use of probiotics was not associ-
ated with changes in BMI, waist circumference, glucose
and lipid levels. Limitations of this study was the small
sample size (n = 10, in each group) [80].
The use of probiotic may be beneficial in management
of pediatric NAFLD. Recent study evaluated the effects
of treatment with Lactobacillus rhamnosus strain GG
(12 billion CFU/day) or placebo for 8 weeks in children
with obesity-related NAFLD. After probiotic treatment
were observed a significant decrease in aminotransferase
activity. From the other hand, concentration of TNF-α
and US bright liver parameters changes insignificantly
and remained fairly stable [81].
The data from these four randomized trials involving
134 NAFLD/NASH patients were summarized in recent
published meta-analysis [82]. The results showed that
probiotic therapy significantly decreased aminotransfer-
ase activity, reduced total-cholesterol and TNF-α levels,
parallel with improvement of insulin resistance. How-
ever, the use of probiotics was not associated with
changes in BMI, glucose (GLU) and low density lipo-
protein (LDL) (BMI: weighted mean difference (WMD)
0.05, 95 % CI: -0.18-0.29, P = 0.64; GLU: WMD 0.05,
95 % CI: -0.25-0.35, P = 0.76; LDL: WMD -0.38, 95 %
CI: -0.78-0.02, P = 0.06).
Recent study found different therapeutic answer on
probiotic administration in NAFLD patients depending
on baseline aminotransferase activity [83]. Totally 72 pa-
tients with type 2 diabetes and NAFLD were included.
Patients of active treated group received multistrain
probiotic “Symbiter” containing concentrated biomass of
14 alive probiotic bacteria of Bibidobacterium, Lactoba-
cillus, Lactococcus, Propionibacterium genera as adjunct
to standard antidiabetic therapy. Statistically significant
reduction of serum proinflammatory cytokines after
30 days of therapy were observed both in patients with
normal or elevated baseline aminotransferase activity,
but in elevated transaminases sub-group these changes
more pronounced. In particular, the level of IL-6 de-
creased on 40 % (p = 0.041), IL-8 - 26.54 % (p <0.001),
TNF-α - 20.83 % (p < 0.001), IL-1β - 17.7 % (p < 0.001)
and interferon (IFN)-γ on 21.84 % (p < 0.001) respect-
ively. In patients with normal levels transaminases and
NAFLD were significantly decreased only IL-6 on 17.1 %
(p = 0.041), IL-8 - 21.4 % (p < 0.001) and TNF-α on
13.8 % (p = 0.008). Patients of comparative group re-
ceived only hypoglycemic drugs. Significant changes in
serum cytokines levels in this were not observed.
Interesting findings were demonstrated in study re-
ported by Shavakhi et al. were probiotic (Protexin two
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Table 2 Summary from clinical studies of impact probiotic strains on obesity and associated diseases
Study Type of study Type of probiotics Duration of intervention Key findings
Kadooka et al. 2010 [72] multicenter, double-blind,
randomized, placebo-controlled
trial
Lactobacillus gasseri SBT2055 12 weeks ↓ abdominal visceral (on 4.6 %) and subcutaneous
(3,3 %) fat areas as measured by CT
↓ body weight and BMI (on 1.5 %)
↑ serum adiponectin
Luoto et al. 2013 [50] randomized, double-blind,
prospective follow-up study
Lactobacillus rhamnosus GG Mothers 4 weeks before expected
delivery with extension for 6 months
postnatally (in children)
↓ weight gain during the first years of life
- most pronounced changes were observed at the
age of 4 years (P = 0.063), with lack of efficiency in
the later stages of development
Vrieze et al. 2012 [75] randomized, double-blind,
parallel, placebo-controlled trial
(FATLOSE trial)
allogenic microbiota from lean
donors to male recipients with
metabolic syndrome or autologous
microbiota
12 weeks ↑ insulin sensitivity (6 weeks after infusion)
↑levels of butyrate-producing intestinal microbiota.
Mazloom et al. 2013 [76] randomized, single- blinded,
placebo-controlled trial
Lactobacillus acidophilus,
L. bulgaricus, L. bifidum, and
L. casei
6 weeks ↓ triglyceride
↓ malondialdehyde (MDA)
↓IL-6 and
↓insulin resistanceAll changes not statistically
significant




3 month ↓ liver aminotransferases levels in patients with
NAFLD
Anthropometric parameters and cardiovascular
risk factors remained unchanged





versus life style modification
24 weeks Bifidobacterium longum with Fos when compared
to lifestyle modification alone, significantly reduces
TNF-α, CRP, serum AST levels, HOMA-IR, serum
endotoxin, steatosis, and the NASH activity index.
Wong et al. 2013 [80] randomized, open label study in
patients with histology-proven
NASH
Lepicol probiotic formula vs
usual care
6 month ↓ intrahepatic triglyceride content (IHTG)
↓ AST level
No changes in BMI, waist circumference, glucose
and lipid levels
Vajro et al. 2011 [81] double-blind, placebo-controlled
pilot study in pediatric NAFLD
Lactobacillus rhamnosus strain GG 8 weeks ↓ALTTNF-α and US bright liver parameters
remained fairly stable
Mykhalchyshyn et al. 2013 [83] open label study in patients
with NAFLD
“Symbiter” containing
concentrated biomass of 14 alive
probiotic bacteria
4 weeks ↓ IL-6, IL-8, TNF-α, IL-1β, IFN-γ (in elevated
transaminases sub-group)
↓ IL-6, IL-8, TNF-α, (in normal transaminases
sub-group)




probiotic Protexin plus Metformin
500 mg (Met/Pro) versus
Metformin 500 mg plus placebo(Met/P)
6 month Probiotic combination with Metformin improves
liver aminotransferases better than metformin
alone. BMI, fasting blood glucose, cholesterol,













tablets per day) in combination with metformin im-
proves liver aminotransferases better than metformin
alone in patients with histologically proven NASH after
6 month of treatment. From the other hand lack of ef-
fectiveness changes for BMI, fasting glycemia, total-
cholesterol and triglyceride were reported in both groups
at the end of treatment [84].
Recent animal and clinical studies have revealed that
probiotics may also improve liver injury in NAFLD. Al-
teration of gut-liver axis plays the pivotal role in the on-
set of fatty liver and related metabolic disturbances. Gut
microbiota not only influences absorption and disposal
of nutrients to the liver, but also can lead to the develop-
ment of “metabolic endotoxemia” and activation of TLR
ligands, which can stimulate liver cells to produce proin-
flammatory cytokines thereby initiate inflammation and
fibrogenesis, which characterize NASH [85]. Another
possible molecular mechanisms which implicated in
NAFLD development are alteration in LPS- endocan-
nabinoid (eCB) system regulatory loops and bile acids
metabolism [62]. Thus, the modification of intestinal
bacterial flora by specific probiotics has been pro-
posed as a therapeutic approach for the treatment of
NAFLD.
Several studies reported that dietary intervention with
yoghurts containing probiotics (Enterococcus faecium,
Streptococcus thermophilus L. acidophilus, Bifidobacter-
ium longum, L. plantarum and/or B. lactis) significantly
reduce total serum cholesterol and LDL cholesterol and
to improve the LDL:HDL cholesterol ratio [86–88]. The
present meta-analysis of controlled short-term interven-
tion studies shows that the fermented yoghurt product
produced a 4 % decrease in total cholesterol and a 5 %
decrease in LDL-cholesterol when the open-label study
is excluded. Different possible mechanism linking impact
of probiotics on lipid metabolism [89]. These include the
physiological action of the end-products of probiotic fer-
mentation (acetate and propionate ratios), bacterial chol-
esterol assimilation, enzymatic deconjugation of bile
acids, and cholesterol binding to the bacterial cell wall
[90]. Some probiotic bacteria strains can affect blood
cholesterol levels by expression of the bacterial enzyme
bile salt hydrolase, which reduced readsorption of se-
creted bile acids, thereby driving the intestinal sink of
cholesterol-derived bile acids and increasing bile acid
synthesis in the liver and subsequent release in the intes-
tine [91, 92]. Data from clinical studies are summarized
in Table 2.
Conclusion
Lifestyle modifications still remain the primary ther-
apy for obesity and the related metabolic disorders.
Most of medications for treatment of obesity are
taken out the production because of their adverse
effects. Novel therapies targeting one or more of the
underlying etiological factors are desirable. One of the
potential ideal strategy for obesity treatment may be
manipulation with gut microbiota. Firstly, this therapy
is safe, due to absence of reported adverse effects,
well-tolerated and appropriate for long-term use. Sec-
ondary, modulation of gut microbiota by probiotic
treatment or dietary intervention due to it beneficial
effects can affect body weight, influence on glucose
and fat metabolism, improve insulin sensitivity and
reduce chronic systemic inflammation. However, most
prominent effect of probiotic on host metabolism
from human studies are reported basically for Lacto-
bacillus and/or Bifidobacterium strains. The general
limitations of all this trials were small sample sizes
and absence of longer-term follow up. Moreover cur-
rently, several potential bacterial candidates, such as
Saccharomyces cerevisiae var. boulardii, Enterobacter
halii or Akkermansia muciniphila have been identified
and novel mechanisms of action governing their
beneficial effects for obesity have been elucidated
[62]. Taking into account all these data the concept
of manipulating the gut microbiota to improve host
metabolism has gained considerable interest now-
adays. More evidence from human trials now needed
to confirm beneficial effects of traditional probiotics
for obesity and to conduct a meta-analysis. Another
important research problem that arose for today be-
came the search for next generation of probiotics for
managing of obesity and its related disorders.
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